Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Stock Competitors & Peer Comparison
See REGN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for REGN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| REGN | $904.35 | +0.16% | 93.6B | 19.82 | $45.63 | +0.41% |
| VRTX | $547.09 | +0.85% | 138.6B | 28.74 | $19.03 | N/A |
| MRNA | $254.19 | +5.27% | 101.5B | -31.20 | -$8.15 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $927.21 | +3.63% | 55.3B | 33.44 | $27.73 | N/A |
| ONC | $406.96 | +5.09% | 43.5B | 71.66 | $5.68 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.90 | +16.47% | 41.4B | -1.12 | -$8.82 | N/A |
| RVMD | $192.28 | +8.24% | 41.2B | -21.79 | -$8.82 | N/A |
| GMAB | $53.63 | +1.69% | 33B | 40.41 | $1.33 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
REGN vs VRTX Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, VRTX has a market cap of 138.6B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while VRTX trades at $547.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas VRTX's P/E ratio is 28.74. In terms of profitability, REGN's ROE is +0.15%, compared to VRTX's ROE of +0.20%. Regarding short-term risk, REGN is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check VRTX's competition here
Moderna, Inc. (NASDAQ: MRNA)
REGN vs MRNA Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, MRNA has a market cap of 101.5B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while MRNA trades at $254.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas MRNA's P/E ratio is -31.20. In terms of profitability, REGN's ROE is +0.15%, compared to MRNA's ROE of -0.38%. Regarding short-term risk, REGN is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for REGN.Check MRNA's competition here
Verona Pharma plc (NASDAQ: VRNA)
REGN vs VRNA Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas VRNA's P/E ratio is -102.80. In terms of profitability, REGN's ROE is +0.15%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, REGN is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for REGN.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
REGN vs ARGX Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, ARGX has a market cap of 55.3B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while ARGX trades at $927.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas ARGX's P/E ratio is 33.44. In terms of profitability, REGN's ROE is +0.15%, compared to ARGX's ROE of +0.17%. Regarding short-term risk, REGN is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ARGX's competition here
BeOne Medicines AG (NASDAQ: ONC)
REGN vs ONC Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, ONC has a market cap of 43.5B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while ONC trades at $406.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas ONC's P/E ratio is 71.66. In terms of profitability, REGN's ROE is +0.15%, compared to ONC's ROE of +0.18%. Regarding short-term risk, REGN is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ONC's competition here
Seagen Inc. (NASDAQ: SGEN)
REGN vs SGEN Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas SGEN's P/E ratio is -57.19. In terms of profitability, REGN's ROE is +0.15%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, REGN is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for REGN.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
REGN vs RVMDW Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, RVMDW has a market cap of 41.4B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while RVMDW trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas RVMDW's P/E ratio is -1.12. In terms of profitability, REGN's ROE is +0.15%, compared to RVMDW's ROE of -0.92%. Regarding short-term risk, REGN is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for REGN.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
REGN vs RVMD Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, RVMD has a market cap of 41.2B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while RVMD trades at $192.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas RVMD's P/E ratio is -21.79. In terms of profitability, REGN's ROE is +0.15%, compared to RVMD's ROE of -0.92%. Regarding short-term risk, REGN is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for REGN.Check RVMD's competition here
Genmab A/S (NASDAQ: GMAB)
REGN vs GMAB Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, GMAB has a market cap of 33B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while GMAB trades at $53.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas GMAB's P/E ratio is 40.41. In terms of profitability, REGN's ROE is +0.15%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, REGN is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for REGN.Check GMAB's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
REGN vs ROIV Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, ROIV has a market cap of 28.1B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while ROIV trades at $38.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas ROIV's P/E ratio is -37.00. In terms of profitability, REGN's ROE is +0.15%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, REGN is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
REGN vs INSM Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, INSM has a market cap of 25.1B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while INSM trades at $114.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas INSM's P/E ratio is -40.59. In terms of profitability, REGN's ROE is +0.15%, compared to INSM's ROE of -0.83%. Regarding short-term risk, REGN is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for REGN.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
REGN vs INCY Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, INCY has a market cap of 24.4B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while INCY trades at $119.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas INCY's P/E ratio is 16.08. In terms of profitability, REGN's ROE is +0.15%, compared to INCY's ROE of +0.07%. Regarding short-term risk, REGN is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for REGN.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
REGN vs UTHR Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, UTHR has a market cap of 24.1B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while UTHR trades at $562.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas UTHR's P/E ratio is 20.11. In terms of profitability, REGN's ROE is +0.15%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, REGN is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for REGN.Check UTHR's competition here
BioNTech SE (NASDAQ: BNTX)
REGN vs BNTX Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, BNTX has a market cap of 21.7B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while BNTX trades at $87.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas BNTX's P/E ratio is -11.35. In terms of profitability, REGN's ROE is +0.15%, compared to BNTX's ROE of -0.08%. Regarding short-term risk, REGN is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check BNTX's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
REGN vs ALNY Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, ALNY has a market cap of 20.9B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while ALNY trades at $155.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas ALNY's P/E ratio is 7.87. In terms of profitability, REGN's ROE is +0.15%, compared to ALNY's ROE of +1.60%. Regarding short-term risk, REGN is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ALNY's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
REGN vs BGNE Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas BGNE's P/E ratio is -22.55. In terms of profitability, REGN's ROE is +0.15%, compared to BGNE's ROE of +0.18%. Regarding short-term risk, REGN is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for REGN.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
REGN vs DNA-WT Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, REGN's ROE is +0.15%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, REGN is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for REGN.Check DNA-WT's competition here
Exelixis, Inc. (NASDAQ: EXEL)
REGN vs EXEL Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, EXEL has a market cap of 17.5B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while EXEL trades at $69.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas EXEL's P/E ratio is 19.87. In terms of profitability, REGN's ROE is +0.15%, compared to EXEL's ROE of +0.46%. Regarding short-term risk, REGN is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for REGN.Check EXEL's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
REGN vs ASND Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, ASND has a market cap of 16.9B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while ASND trades at $256.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas ASND's P/E ratio is -106.12. In terms of profitability, REGN's ROE is +0.15%, compared to ASND's ROE of +1.90%. Regarding short-term risk, REGN is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
REGN vs NBIX Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, NBIX has a market cap of 16.7B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while NBIX trades at $164.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas NBIX's P/E ratio is 23.79. In terms of profitability, REGN's ROE is +0.15%, compared to NBIX's ROE of +0.20%. Regarding short-term risk, REGN is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
REGN vs JAZZ Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, JAZZ has a market cap of 15.1B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while JAZZ trades at $234.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas JAZZ's P/E ratio is 8.75. In terms of profitability, REGN's ROE is +0.15%, compared to JAZZ's ROE of +0.05%. Regarding short-term risk, REGN is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for REGN.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
REGN vs BBIO Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, BBIO has a market cap of 14.5B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while BBIO trades at $74.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas BBIO's P/E ratio is -24.43. In terms of profitability, REGN's ROE is +0.15%, compared to BBIO's ROE of +0.27%. Regarding short-term risk, REGN is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for REGN.Check BBIO's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
REGN vs SMMT Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, SMMT has a market cap of 13B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while SMMT trades at $16.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas SMMT's P/E ratio is -14.58. In terms of profitability, REGN's ROE is +0.15%, compared to SMMT's ROE of -1.59%. Regarding short-term risk, REGN is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for REGN.Check SMMT's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
REGN vs KRTX Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas KRTX's P/E ratio is -28.09. In terms of profitability, REGN's ROE is +0.15%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, REGN is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check KRTX's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
REGN vs HALO Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, HALO has a market cap of 11.8B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while HALO trades at $103.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas HALO's P/E ratio is 19.35. In terms of profitability, REGN's ROE is +0.15%, compared to HALO's ROE of +5.44%. Regarding short-term risk, REGN is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for REGN.Check HALO's competition here
Bio-Techne Corporation (NASDAQ: TECH)
REGN vs TECH Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while TECH trades at $72.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas TECH's P/E ratio is 37.52. In terms of profitability, REGN's ROE is +0.15%, compared to TECH's ROE of +0.09%. Regarding short-term risk, REGN is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for REGN.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
REGN vs RNAM Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas RNAM's P/E ratio is -17.39. In terms of profitability, REGN's ROE is +0.15%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, REGN is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for REGN.Check RNAM's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
REGN vs KYMR Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, KYMR has a market cap of 11.2B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while KYMR trades at $131.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas KYMR's P/E ratio is -36.38. In terms of profitability, REGN's ROE is +0.15%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, REGN is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for REGN.Check KYMR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
REGN vs BMRN Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, BMRN has a market cap of 10.8B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while BMRN trades at $56.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas BMRN's P/E ratio is 26.93. In terms of profitability, REGN's ROE is +0.15%, compared to BMRN's ROE of -0.00%. Regarding short-term risk, REGN is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for REGN.Check BMRN's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
REGN vs PCVX Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, PCVX has a market cap of 10B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while PCVX trades at $63.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas PCVX's P/E ratio is -8.37. In terms of profitability, REGN's ROE is +0.15%, compared to PCVX's ROE of -0.42%. Regarding short-term risk, REGN is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check PCVX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
REGN vs SYRE Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, SYRE has a market cap of 9.6B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while SYRE trades at $103.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas SYRE's P/E ratio is -53.26. In terms of profitability, REGN's ROE is +0.15%, compared to SYRE's ROE of -0.30%. Regarding short-term risk, REGN is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for REGN.Check SYRE's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
REGN vs RXDX Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas RXDX's P/E ratio is -56.47. In terms of profitability, REGN's ROE is +0.15%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, REGN is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check RXDX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
REGN vs MDGL Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, MDGL has a market cap of 9.2B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while MDGL trades at $399.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas MDGL's P/E ratio is -31.27. In terms of profitability, REGN's ROE is +0.15%, compared to MDGL's ROE of -0.27%. Regarding short-term risk, REGN is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for REGN.Check MDGL's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
REGN vs TGTX Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, TGTX has a market cap of 9.2B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while TGTX trades at $59.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas TGTX's P/E ratio is 21.68. In terms of profitability, REGN's ROE is +0.15%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, REGN is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check TGTX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
REGN vs IBRX Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, IBRX has a market cap of 9.1B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while IBRX trades at $8.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas IBRX's P/E ratio is -8.90. In terms of profitability, REGN's ROE is +0.15%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, REGN is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check IBRX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
REGN vs NUVL Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas NUVL's P/E ratio is -21.79. In terms of profitability, REGN's ROE is +0.15%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, REGN is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for REGN.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
REGN vs CRNX Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas CRNX's P/E ratio is -16.86. In terms of profitability, REGN's ROE is +0.15%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, REGN is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check CRNX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
REGN vs KRYS Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, KRYS has a market cap of 8.9B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while KRYS trades at $300.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas KRYS's P/E ratio is 37.68. In terms of profitability, REGN's ROE is +0.15%, compared to KRYS's ROE of +0.17%. Regarding short-term risk, REGN is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for REGN.Check KRYS's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
REGN vs IMGN Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas IMGN's P/E ratio is -111.55. In terms of profitability, REGN's ROE is +0.15%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, REGN is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for REGN.Check IMGN's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
REGN vs PTGX Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, PTGX has a market cap of 8.5B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while PTGX trades at $132.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas PTGX's P/E ratio is 128.05. In terms of profitability, REGN's ROE is +0.15%, compared to PTGX's ROE of +0.43%. Regarding short-term risk, REGN is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check PTGX's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
REGN vs APGE Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas APGE's P/E ratio is -31.19. In terms of profitability, REGN's ROE is +0.15%, compared to APGE's ROE of -0.30%. Regarding short-term risk, REGN is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for REGN.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
REGN vs BPMC Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas BPMC's P/E ratio is -51.58. In terms of profitability, REGN's ROE is +0.15%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, REGN is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for REGN.Check BPMC's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
REGN vs ARWR Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, ARWR has a market cap of 8.2B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while ARWR trades at $58.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas ARWR's P/E ratio is -25.84. In terms of profitability, REGN's ROE is +0.15%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, REGN is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ARWR's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
REGN vs CERE Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas CERE's P/E ratio is -16.47. In terms of profitability, REGN's ROE is +0.15%, compared to CERE's ROE of -0.72%. Regarding short-term risk, REGN is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for REGN.Check CERE's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
REGN vs TWST Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, TWST has a market cap of 8B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while TWST trades at $120.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas TWST's P/E ratio is -54.47. In terms of profitability, REGN's ROE is +0.15%, compared to TWST's ROE of -0.30%. Regarding short-term risk, REGN is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for REGN.Check TWST's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
REGN vs PRAX Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, PRAX has a market cap of 7.8B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while PRAX trades at $277.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas PRAX's P/E ratio is -21.49. In terms of profitability, REGN's ROE is +0.15%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, REGN is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check PRAX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
REGN vs RYTM Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, RYTM has a market cap of 7.7B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while RYTM trades at $112.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas RYTM's P/E ratio is -36.07. In terms of profitability, REGN's ROE is +0.15%, compared to RYTM's ROE of -0.84%. Regarding short-term risk, REGN is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for REGN.Check RYTM's competition here
Abivax S.A. (NASDAQ: ABVX)
REGN vs ABVX Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, ABVX has a market cap of 7.5B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while ABVX trades at $85.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas ABVX's P/E ratio is -14.06. In terms of profitability, REGN's ROE is +0.15%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, REGN is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ABVX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
REGN vs CYTK Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, CYTK has a market cap of 7.5B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while CYTK trades at $53.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas CYTK's P/E ratio is -7.44. In terms of profitability, REGN's ROE is +0.15%, compared to CYTK's ROE of +1.57%. Regarding short-term risk, REGN is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for REGN.Check CYTK's competition here
Metsera, Inc. (NASDAQ: MTSR)
REGN vs MTSR Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas MTSR's P/E ratio is -23.58. In terms of profitability, REGN's ROE is +0.15%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, REGN is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for REGN.Check MTSR's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
REGN vs CAI Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, CAI has a market cap of 7.1B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while CAI trades at $25.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas CAI's P/E ratio is 70.92. In terms of profitability, REGN's ROE is +0.15%, compared to CAI's ROE of +0.16%. Regarding short-term risk, REGN is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for REGN.Check CAI's competition here
10x Genomics, Inc. (NASDAQ: TXG)
REGN vs TXG Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, TXG has a market cap of 7.1B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while TXG trades at $59.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas TXG's P/E ratio is -100.53. In terms of profitability, REGN's ROE is +0.15%, compared to TXG's ROE of -0.08%. Regarding short-term risk, REGN is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for REGN.Check TXG's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
REGN vs AXSM Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, AXSM has a market cap of 7B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while AXSM trades at $132.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas AXSM's P/E ratio is -34.56. In terms of profitability, REGN's ROE is +0.15%, compared to AXSM's ROE of -1.90%. Regarding short-term risk, REGN is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for REGN.Check AXSM's competition here
Merus N.V. (NASDAQ: MRUS)
REGN vs MRUS Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas MRUS's P/E ratio is -17.05. In terms of profitability, REGN's ROE is +0.15%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, REGN is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for REGN.Check MRUS's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
REGN vs ORKA Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, ORKA has a market cap of 6.8B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while ORKA trades at $102.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas ORKA's P/E ratio is -52.98. In terms of profitability, REGN's ROE is +0.15%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, REGN is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ORKA's competition here
CG Oncology Inc. (NASDAQ: CGON)
REGN vs CGON Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, CGON has a market cap of 6.7B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while CGON trades at $75.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas CGON's P/E ratio is -28.25. In terms of profitability, REGN's ROE is +0.15%, compared to CGON's ROE of -0.19%. Regarding short-term risk, REGN is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for REGN.Check CGON's competition here
Arcellx, Inc. (NASDAQ: ACLX)
REGN vs ACLX Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas ACLX's P/E ratio is -28.27. In terms of profitability, REGN's ROE is +0.15%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, REGN is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
REGN vs RETA Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas RETA's P/E ratio is -66.29. In terms of profitability, REGN's ROE is +0.15%, compared to RETA's ROE of +0.47%. Regarding short-term risk, REGN is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for REGN.Check RETA's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
REGN vs IONS Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, IONS has a market cap of 6.5B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while IONS trades at $39.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas IONS's P/E ratio is -12.05. In terms of profitability, REGN's ROE is +0.15%, compared to IONS's ROE of -1.11%. Regarding short-term risk, REGN is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for REGN.Check IONS's competition here
Immunovant, Inc. (NASDAQ: IMVT)
REGN vs IMVT Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, IMVT has a market cap of 6.3B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while IMVT trades at $30.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas IMVT's P/E ratio is -10.82. In terms of profitability, REGN's ROE is +0.15%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, REGN is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for REGN.Check IMVT's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
REGN vs CNTA Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas CNTA's P/E ratio is -22.63. In terms of profitability, REGN's ROE is +0.15%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, REGN is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for REGN.Check CNTA's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
REGN vs KOD Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, KOD has a market cap of 6.2B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while KOD trades at $99.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas KOD's P/E ratio is -23.82. In terms of profitability, REGN's ROE is +0.15%, compared to KOD's ROE of -2.73%. Regarding short-term risk, REGN is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for REGN.Check KOD's competition here
Belite Bio, Inc (NASDAQ: BLTE)
REGN vs BLTE Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, BLTE has a market cap of 6.1B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while BLTE trades at $154.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas BLTE's P/E ratio is -82.52. In terms of profitability, REGN's ROE is +0.15%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, REGN is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for REGN.Check BLTE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
REGN vs LGND Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, LGND has a market cap of 6.1B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while LGND trades at $306.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas LGND's P/E ratio is 33.58. In terms of profitability, REGN's ROE is +0.15%, compared to LGND's ROE of +0.05%. Regarding short-term risk, REGN is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for REGN.Check LGND's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
REGN vs TERN Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas TERN's P/E ratio is -51.41. In terms of profitability, REGN's ROE is +0.15%, compared to TERN's ROE of -0.14%. Regarding short-term risk, REGN is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for REGN.Check TERN's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
REGN vs MIRM Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, MIRM has a market cap of 6.1B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while MIRM trades at $93.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas MIRM's P/E ratio is -6.44. In terms of profitability, REGN's ROE is +0.15%, compared to MIRM's ROE of -7.34%. Regarding short-term risk, REGN is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for REGN.Check MIRM's competition here
Veradermics, Incorporated (NYSE: MANE)
REGN vs MANE Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, MANE has a market cap of 5.8B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while MANE trades at $138.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas MANE's P/E ratio is -44.17. In terms of profitability, REGN's ROE is +0.15%, compared to MANE's ROE of -0.38%. Regarding short-term risk, REGN is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for REGN.Check MANE's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
REGN vs SRRK Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while SRRK trades at $46.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas SRRK's P/E ratio is -13.60. In terms of profitability, REGN's ROE is +0.15%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, REGN is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for REGN.Check SRRK's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
REGN vs CDTX Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas CDTX's P/E ratio is -19.77. In terms of profitability, REGN's ROE is +0.15%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, REGN is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
REGN vs ABCM Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, REGN's ROE is +0.15%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, REGN is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for REGN.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
REGN vs ISEE Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas ISEE's P/E ratio is -22.44. In terms of profitability, REGN's ROE is +0.15%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, REGN is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for REGN.Check ISEE's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
REGN vs COGT Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, COGT has a market cap of 5.5B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while COGT trades at $31.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas COGT's P/E ratio is -15.00. In terms of profitability, REGN's ROE is +0.15%, compared to COGT's ROE of -0.71%. Regarding short-term risk, REGN is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for REGN.Check COGT's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
REGN vs PTCT Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while PTCT trades at $65.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas PTCT's P/E ratio is -46.74. In terms of profitability, REGN's ROE is +0.15%, compared to PTCT's ROE of +0.57%. Regarding short-term risk, REGN is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for REGN.Check PTCT's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
REGN vs APLS Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas APLS's P/E ratio is 38.35. In terms of profitability, REGN's ROE is +0.15%, compared to APLS's ROE of +0.40%. Regarding short-term risk, REGN is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for REGN.Check APLS's competition here
Erasca, Inc. (NASDAQ: ERAS)
REGN vs ERAS Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, ERAS has a market cap of 5B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while ERAS trades at $14.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas ERAS's P/E ratio is -15.49. In terms of profitability, REGN's ROE is +0.15%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, REGN is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ERAS's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
REGN vs CRSP Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, CRSP has a market cap of 4.9B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while CRSP trades at $50.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas CRSP's P/E ratio is -10.52. In terms of profitability, REGN's ROE is +0.15%, compared to CRSP's ROE of -0.26%. Regarding short-term risk, REGN is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for REGN.Check CRSP's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
REGN vs EWTX Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, EWTX has a market cap of 4.9B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while EWTX trades at $45.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas EWTX's P/E ratio is -24.37. In terms of profitability, REGN's ROE is +0.15%, compared to EWTX's ROE of +1.30%. Regarding short-term risk, REGN is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check EWTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
REGN vs DNTH Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, DNTH has a market cap of 4.8B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while DNTH trades at $86.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas DNTH's P/E ratio is -20.72. In terms of profitability, REGN's ROE is +0.15%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, REGN is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for REGN.Check DNTH's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
REGN vs TVTX Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, TVTX has a market cap of 4.8B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while TVTX trades at $49.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas TVTX's P/E ratio is -110.27. In terms of profitability, REGN's ROE is +0.15%, compared to TVTX's ROE of -1.86%. Regarding short-term risk, REGN is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check TVTX's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
REGN vs FOLD Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas FOLD's P/E ratio is -161.00. In terms of profitability, REGN's ROE is +0.15%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, REGN is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for REGN.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
REGN vs AKRO Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas AKRO's P/E ratio is -14.57. In terms of profitability, REGN's ROE is +0.15%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, REGN is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for REGN.Check AKRO's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
REGN vs DFTX Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, DFTX has a market cap of 4.5B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while DFTX trades at $33.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas DFTX's P/E ratio is N/A. In terms of profitability, REGN's ROE is +0.15%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, REGN is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check DFTX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
REGN vs ADPT Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, ADPT has a market cap of 4.5B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while ADPT trades at $27.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas ADPT's P/E ratio is -68.20. In terms of profitability, REGN's ROE is +0.15%, compared to ADPT's ROE of -0.37%. Regarding short-term risk, REGN is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ADPT's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
REGN vs ALPN Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas ALPN's P/E ratio is -101.52. In terms of profitability, REGN's ROE is +0.15%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, REGN is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for REGN.Check ALPN's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
REGN vs LEGN Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, LEGN has a market cap of 4.3B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while LEGN trades at $23.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas LEGN's P/E ratio is -34.41. In terms of profitability, REGN's ROE is +0.15%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, REGN is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for REGN.Check LEGN's competition here
Opthea Limited (NASDAQ: OPT)
REGN vs OPT Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas OPT's P/E ratio is -1.52. In terms of profitability, REGN's ROE is +0.15%, compared to OPT's ROE of +1.18%. Regarding short-term risk, REGN is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for REGN.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
REGN vs PRTC Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas PRTC's P/E ratio is -3.78. In terms of profitability, REGN's ROE is +0.15%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, REGN is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for REGN.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
REGN vs MRTX Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas MRTX's P/E ratio is -4.82. In terms of profitability, REGN's ROE is +0.15%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, REGN is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check MRTX's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
REGN vs RLAY Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, RLAY has a market cap of 4.1B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while RLAY trades at $18.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas RLAY's P/E ratio is -11.85. In terms of profitability, REGN's ROE is +0.15%, compared to RLAY's ROE of -0.40%. Regarding short-term risk, REGN is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for REGN.Check RLAY's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
REGN vs CPRX Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas CPRX's P/E ratio is 17.49. In terms of profitability, REGN's ROE is +0.15%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, REGN is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check CPRX's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
REGN vs ABCL Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while ABCL trades at $11.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas ABCL's P/E ratio is -22.01. In terms of profitability, REGN's ROE is +0.15%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, REGN is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ABCL's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
REGN vs XENE Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, XENE has a market cap of 3.8B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while XENE trades at $39.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas XENE's P/E ratio is -8.34. In terms of profitability, REGN's ROE is +0.15%, compared to XENE's ROE of -0.44%. Regarding short-term risk, REGN is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for REGN.Check XENE's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
REGN vs RYZB Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas RYZB's P/E ratio is -57.86. In terms of profitability, REGN's ROE is +0.15%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, REGN is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for REGN.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
REGN vs CBAY Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas CBAY's P/E ratio is -32.81. In terms of profitability, REGN's ROE is +0.15%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, REGN is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for REGN.Check CBAY's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
REGN vs AMLX Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, AMLX has a market cap of 3.7B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while AMLX trades at $29.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas AMLX's P/E ratio is -19.68. In terms of profitability, REGN's ROE is +0.15%, compared to AMLX's ROE of -0.42%. Regarding short-term risk, REGN is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check AMLX's competition here
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD)
REGN vs ACAD Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while ACAD trades at $21.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas ACAD's P/E ratio is 9.56. In terms of profitability, REGN's ROE is +0.15%, compared to ACAD's ROE of +0.28%. Regarding short-term risk, REGN is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ACAD's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
REGN vs IOVA Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, IOVA has a market cap of 3.6B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while IOVA trades at $8.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas IOVA's P/E ratio is -11.01. In terms of profitability, REGN's ROE is +0.15%, compared to IOVA's ROE of -0.30%. Regarding short-term risk, REGN is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for REGN.Check IOVA's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
REGN vs ELVN Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, ELVN has a market cap of 3.6B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while ELVN trades at $49.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas ELVN's P/E ratio is -29.63. In terms of profitability, REGN's ROE is +0.15%, compared to ELVN's ROE of -0.17%. Regarding short-term risk, REGN is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ELVN's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
REGN vs TNGX Comparison November 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 93.6B. In comparison, TNGX has a market cap of 3.6B. Regarding current trading prices, REGN is priced at $904.35 on the NASDAQ, while TNGX trades at $21.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 19.82, whereas TNGX's P/E ratio is -25.89. In terms of profitability, REGN's ROE is +0.15%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, REGN is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check TNGX's competition here